Stockscreener 앱 받기
1.79
9.14%
-0.18
전일 마감가:
$1.97
열려 있는:
$1.96
하루 거래량:
61,755
Relative Volume:
2.67
시가총액:
$5.53M
수익:
$4.33M
순이익/손실:
$-4.17M
주가수익비율:
-1.1971
EPS:
-1.4953
순현금흐름:
$-3.19M
1주 성능:
-14.35%
1개월 성능:
-20.44%
6개월 성능:
-23.83%
1년 성능:
-45.26%
1일 변동 폭
$1.79
$2.00
1주일 범위
$1.79
$2.11
52주 변동 폭
$1.79
$4.60
Biomerica Inc Stock (BMRA) Company Profile
명칭
Biomerica Inc
전화
(949) 379-2875
주소
17571 VON KARMAN AVENUE, IRVINE, CA
Compare BMRA vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMRA
Biomerica Inc
|
1.79 | 5.53M | 4.33M | -4.17M | -3.19M | -1.4953 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Biomerica Inc Stock (BMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-11-10 | 개시 | Colliers Securities | Buy |
| 2018-01-04 | 개시 | B. Riley FBR, Inc. | Buy |
Biomerica Inc 주식(BMRA)의 최신 뉴스
Biomerica Inc (BMRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biomerica Inc (BMRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomerica Inc (BMRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomerica Inc (BMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomerica Inc (BMRA) Institutional Confidence - TradingKey
Biomerica Inc (BMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomerica Inc (BMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomerica Inc (BMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biomerica Inc (BMRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomerica (BMRA) Slips Slightly to $2.05; Near Key Support Amid Quiet TradingDark Pool Volume - newsline.com
Biomerica (BMRA) Edges Lower, Testing Key Support at $1.95ETF Liquidity - newsline.com
Biomerica (BMRA) Edges Higher as Stock Holds Above Key Support LevelIV Contraction - newsline.com
BMRA Q1 2026 Earnings: Net Loss of $0.44 per Share; Stock Declines 0.92%Analyst Consensus Shift - newsline.com
Biomerica (BMRA) Slides Slightly as Stock Approaches Key Support LevelIceberg Order - newsline.com
Biomerica (BMRA) Q1 2026 Earnings: Narrowing Loss Amid Ongoing Operational ChallengesReturn On Capital - newsline.com
Biomerica, Inc. Announces $500,000 Securities Purchase Agreement and Secured Promissory Note – Form 8-K Filing, May 29, 2026 – Minichart - Minichart
Biomerica Enters Related-Party Deal to Boost Liquidity - TipRanks
Biomerica to Sell 6% Diagnosis Stake for $500,000; Issues 8% Note Pending Transfer - TradingView
Biomerica (BMRA) sells 6% Diagnosis S.A. stake to CEO-affiliated buyers - Stock Titan
Biomerica Inc. (BMRA) Sees Modest Gain as Shares Test Key ResistanceDip Buy Trade - newsline.com
BMRA Q1 2026 Earnings: Operating Loss Widens to $0.44 per Share as Pre-Revenue Biotech Advances Pipeline - newsline.com
Biomerica secures USD 1.75M contract for IVD diagnostic development - Medical Buyer
BMRA Stock Price, Quote & Chart | BIOMERICA INC (NASDAQ:BMRA) - ChartMill
Biomerica Inc. Awarded $1.75 Million Contract for IVD Product Development - geneonline.com
Biomerica (BMRA) Secures Master Services Agreement for Diagnosti - GuruFocus
Biomerica Inc. (BMRA) Holds Near Support Amid Modest PullbackBeta Neutral Pair - The Legal Advocate
Biomerica Wins $1.75M Contract to Develop Diagnostic Tests - Orange County Business Journal
Biomerica signs contract development deal worth over $1.75M By Investing.com - Investing.com Canada
Biomerica lands $1.75 million CDMO master services agreement for IVD diagnostic development - marketscreener.com
Biomerica signs contract development deal worth over $1.75M - Investing.com
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development - The Manila Times
Undisclosed $1.75M lab deal taps Biomerica’s diagnostic test expertise - Stock Titan
Biomerica Q1 2026 Earnings: Net Loss of $0.44 Per Share Amid Lack of Revenue DisclosureManagement Guidance Update - The Legal Advocate
Biomerica Inc. (BMRA) Q1 2026 Earnings: Negative EPS Persists Amid Pre-Revenue StageEarnings Season Review - The Legal Advocate
BMRA Q1 2026 Earnings: Biomerica Reports Net Loss of $0.44 Per Share Amid Ongoing Development Efforts - Newser
Biomerica (BMRA) Q1 2026 Earnings: Revenue $N/A, Matching ViewsExpert Entry Points - Newser
ConsumerDirect names Gary Lu as chief financial officer - Investing.com UK
ConsumerDirect names Gary Lu as chief financial officer By Investing.com - Investing.com South Africa
ConsumerDirect adds new CFO to scale its subscription business - Stock Titan
Biomerica (BMRA) Stock Analysis: Falls -3.85%, Watching $2.14 2026-05-18Most Watched Stocks - newser.com
Should You Sell Biomerica (BMRA) After -2.90% Drop? 2026-05-17Crowd Sentiment Stocks - Newser
TradingKey - TradingKey
What Biomerica (BMRA) subscription metrics reveal about retention | BMRA Q1 2026: Biomerica Posts Wider Loss Amid Cost PressureCatalyst Event - Newser
BMRA | BIOMERICA INC Insider Trading - Quiver Quantitative
What nobody tells you about Biomerica (BMRA) stock (Smart Money Outflows) 2026-05-08Value ETF - The Legal Advocate
Why are smart money investors paying attention to Biomerica (BMRA)? (On the Radar) 2026-05-07Verified Stock Signals - newser.com
How Biomerica (BMRA) competitive position is evolving (Bullish Momentum) 2026-05-06Social Investment Platform - newser.com
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026 - Weekly Voice
An IBS diet-guided therapy gets a slot at the world's biggest GI meeting - Stock Titan
BMRA (Biomerica) falls 0.47% after reporting Q1 2026 negative EPS of $-0.44 with no available analyst consensus estimates.Cash Flow Report - The Legal Advocate
BMRA (Biomerica Inc.) posts 1.9 percent year-over-year Q1 2026 revenue dip, shares gain 4.27 percent. - Cổng thông tin điện tử tỉnh Lào Cai
Biomerica Inc (BMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
자본화:
|
볼륨(24시간):